119 related articles for article (PubMed ID: 37778965)
21. Corrigendum to "Salidroside postconditioning attenuates ferroptosis-mediated lung ischemia-reperfusion injury by activating the Nrf2/SLC7A11 signaling axis" [Int. Immunopharmacol. 115 (2023) 109731].
Wang Y; Chen Z; Luo J; Zhang J; Sang AM; Cheng ZS; Li XY
Int Immunopharmacol; 2023 Apr; 117():110002. PubMed ID: 36925352
[No Abstract] [Full Text] [Related]
22. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
23. Corrigendum to "Methylallyl sulfone attenuates inflammation, oxidative stress and lung injury induced by cigarette smoke extract in mice and RAW264.7 cells" Int Immunopharmacol, volume 59, 2018, 369-374.
Li A; Liu Y; Zhu X; Sun X; Feng X; Li D; Zhang J; Zhu M; Zhao Z
Int Immunopharmacol; 2019 Jul; 72():522. PubMed ID: 30922802
[No Abstract] [Full Text] [Related]
24. Corrigendum to "Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells" [Int. Immunopharmacol. 125(Part A) (2023) 111139].
Feng Q; Hu K; Hu H; Lu Y; Zhang H; Wang G; Zhang Q; Xu Z; Gao X; Jia X; Zhu H; Song D; Yi H; Peng Y; Wu X; Li B; Zhu W; Shi J
Int Immunopharmacol; 2024 Jun; ():112499. PubMed ID: 38909009
[No Abstract] [Full Text] [Related]
25. Corrigendum to "Zerumbone enhances the Th1 response and ameliorates ovalbumin-induced Th2 responses and airway inflammation in mice" [Int. Immunopharmacol. 24 (2015) 383-391].
Shieh YH; Huang HM; Ching-Chiung Wang ; Lee CC; Fan CK; Lee YL
Int Immunopharmacol; 2017 Sep; 50():371. PubMed ID: 28751107
[No Abstract] [Full Text] [Related]
26. Corrigendum to "Pmepa1 knockdown alleviates SpA-induced pyroptosis and osteogenic differentiation inhibition of hBMSCs via p38MAPK/NLRP3 axis" [Int. Immunopharmacol. 124(Part A) (2023) 110843].
Li M; Shi X; Wu Y; Qi B; Zhang C; Wang B; Zhang B; Xu Y
Int Immunopharmacol; 2023 Nov; 124(Pt A):111013. PubMed ID: 37806790
[No Abstract] [Full Text] [Related]
27. Corrigendum to "Monotropein exerts protective effects against IL-1β-induced apoptosis and catabolic responses on osteoarthritis chondrocytes" [Int. Immunopharmacol. 23(2) (2014) 575-580].
Wang F; Wu L; Li L; Chen S
Int Immunopharmacol; 2023 Mar; 116():109633. PubMed ID: 36780829
[No Abstract] [Full Text] [Related]
28. Corrigendum to "GTS-21 attenuates ACE/ACE2 ratio and glycocalyx shedding in lipopolysaccharide-induced acute lung injury by targeting macrophage polarization derived ADAM-17" [Int. Immunopharmacol. 129 (2024) 111603].
Zhu W; Wang F; Hu C; Zhao Q; Zhang D; Wang X; Hu B; Li J
Int Immunopharmacol; 2024 May; 132():111914. PubMed ID: 38582738
[No Abstract] [Full Text] [Related]
29. Corrigendum to "Oridonin regulates the polarized state of Kupffer cells to alleviate nonalcoholic fatty liver disease through ROS-NF-κB" [Int. Immunopharmacol. 101(Part B) (2021) 108290].
Zhu Y; Ruan S; Shen H; Guan Q; Zhai L; Yang Y
Int Immunopharmacol; 2023 Jun; 119():110302. PubMed ID: 37193623
[No Abstract] [Full Text] [Related]
30. Corrigendum to "Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies" [Int. Immunopharmacol. 113(Part A) (2022) 109331].
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2023 Jan; 114():109555. PubMed ID: 36527876
[No Abstract] [Full Text] [Related]
31. Corrigendum to "Tryptase inhibitor APC 366 prevents hepatic fibrosis by inhibiting collagen synthesis induced by tryptase/protease-activated receptor 2 interactions in hepatic stellate cells" [Int. Immunopharmacol. 20 (2014) 352-357].
Lu J; Chen B; Li S; Sun Q
Int Immunopharmacol; 2019 Apr; 69():408. PubMed ID: 30755386
[No Abstract] [Full Text] [Related]
32. Corrigendum to "Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants" [Int. Immunopharmacol. 101(Part B) (2021) 108216].
He L; Sun B; Guo Y; Yan K; Liu D; Zang Y; Jiang C; Zhang Y; Kong W
Int Immunopharmacol; 2023 Jun; 119():110260. PubMed ID: 37150708
[No Abstract] [Full Text] [Related]
33. Corrigendum to "Epigallocatechin gallate potentially abrogates fluoride induced lung oxidative stress, inflammation via Nrf2/Keap1 signaling pathway in rats: An in-vivo and in-silico study" [Int. Immunopharmacol. 39 (2016) 128-139].
Shanmugam T; Selvaraj M; Poomalai S
Int Immunopharmacol; 2020 Mar; 80():106203. PubMed ID: 31983588
[No Abstract] [Full Text] [Related]
34. Corrigendum to "IDO1: An important immunotherapy target in cancer treatment" [Int. Immunopharmacol. 47 (2017) 70-77].
Li F; Zhang R; Li S; Liu J
Int Immunopharmacol; 2017 Aug; 49():231. PubMed ID: 28457914
[No Abstract] [Full Text] [Related]
35. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
36. Corrigendum to "Effect of chlorogenic acid on mast cell-dependent anaphylactic reaction" [Int. Immunopharmacol. 10 (2010) 1135-1141].
Qin HD; Shi YQ; Liu ZH; Li ZG; Wang HS; Wang H; Liu ZP
Int Immunopharmacol; 2019 Nov; 76():105863. PubMed ID: 31473097
[No Abstract] [Full Text] [Related]
37. Corrigendum to "Cynapanoside A exerts protective effects against obesity-induced diabetic nephropathy through ameliorating TRIM31-mediated inflammation, lipid synthesis and fibrosis" [Int. Immunopharmacol. 113 (Part B) (2022) 109395].
Luo J; Tan J; Zhao J; Wang L; Liu J; Dai X; Sun Y; Kuang Q; Hui J; Chen J; Kuang G; Chen S; Wang Y; Ge C; Xu M
Int Immunopharmacol; 2023 Dec; 125(Pt A):111119. PubMed ID: 37907388
[No Abstract] [Full Text] [Related]
38. Corrigendum to "Oleamide suppresses inflammatory responses in LPS-induced RAW264.7 murine macrophages and alleviates paw edema in a carrageenan-induced inflammatory rat model" [Int. Immunopharmacol. 56 (2018) 179-185].
Moon SM; Lee SA; Hong JH; Kim JS; Kim DK; Kim CS
Int Immunopharmacol; 2018 Jul; 60():246. PubMed ID: 29789261
[No Abstract] [Full Text] [Related]
39. Corrigendum to "Modulating endoplasmic reticulum stress attenuates mast cell degranulation" [Int. Immunopharmacol. 126 (2024) 111336].
Fan J; Ma L; Xie B; Qiu S; Song S; Tang Z; Wu Y; Huangfu H; Feng Y; Luo X; Yang P
Int Immunopharmacol; 2024 Jun; ():112497. PubMed ID: 38902129
[No Abstract] [Full Text] [Related]
40. Corrigendum to "Salvianolic acid B inhibits hepatic stellate cell activation and liver fibrosis by targeting PDGFRβ" [Int. Immunopharmacol. 122 (2023) 110550].
Liu F; Li S; Chen P; Gu Y; Wang S; Wang L; Chen C; Wang R; Yuan Y
Int Immunopharmacol; 2023 Oct; 123():110790. PubMed ID: 37640621
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
